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Abstract
Background: Ventilator associated pneumonia (VAP) is a serious infection among patients in the intensive care unit (ICU).
Methods: We reviewed the medical charts of all patients admitted to the adult intensive care units of the Massachusetts
General Hospital that went on to develop VAP during a five year period.
Results: 200 patients were included in the study of which 50 (25%) were infected with a multidrug resistant pathogen.
Increased age, dialysis and late onset ($5 days from admission) VAP were associated with increased incidence of resistance.
Multidrug resistant bacteria (MDRB) isolation was associated with a significant increase in median length of ICU stay (19 vs.
16 days, p=0.02) and prolonged duration of mechanical ventilation (18 vs. 14 days, p=0.03), but did not impact overall
mortality (HR 1.12, 95% CI 0.51–2.46, p=0.77). However, age (HR 1.04 95% CI 1.01–1.07, p=0.003) was an independent risk
factor for mortality and age $65 years was associated with increased incidence of methicillin-resistant Staphylococcus
aureus (MRSA) infections (OR 2.83, 95% CI 1.27–6.32, p=0.01).
Conclusions: MDRB-related VAP is associated with prolonged ICU stay and mechanical ventilation. Interestingly, age $ 65
years is associated with MRSA VAP.
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Introduction
Infectious complications are amongst the dominant causes of
morbidity and mortality in hospitalized patients and especially in
the Intensive Care Unit (ICU) setting. Indeed, recent data estimate
that health-care associated infections lead to annual costs of $9.8
billion [1]. The emergence of antimicrobial resistant pathogens
further aggravates this problem rendering most of our antibacterial
armory useless. To alert the scientific community on the
importance of this issue, the world economic forum stated that
antibiotic-resistant bacteria arguably pose the greatest risk to
human health worldwide [2]. One of the most notorious among
the health-care associated infections is hospital-acquired pneumo-
nia, the most important subset of which, ventilator-associated
pneumonia (VAP) accounts for 36.1% of the total annual costs
associated with these diseases [1].
Currently, VAP is recognized as arguably the most important
ICU-related infection with an incidence that ranges from two to
sixteen cases per 1000 ventilator-days [3]. Its indubitable
association with significant increases in length of ICU stay and
mechanical ventilation has recently led to the widespread
implementation of measures to prevent its occurrence and
decrease the burden of disease [4,5]. Importantly, VAP is often
associated with strikingly high rates of multidrug resistant bacteria
(MDRB), further complicating its already arduous nature [6].
Finally patients with VAP are commonly colonized in their upper
respiratory tract with microbes that are not directly associated with
the infection but can significantly affect it. Candida spp. might be an
important microbe in this context [7-9].
Methods
We conducted a retrospective cohort study of all consecutive
non-overlapping, adult patients with VAP that received their care
at the medical or surgical ICUs of the Massachusetts General
Hospital (MGH) between August 2005 and November 2011. This
includes a general medical ICU, a neurosciences ICU, a general
surgical ICU, a cardiac-surgical ICU, a coronary care unit, a
transplant and a burn ICU. The study was approved by the MGH
Institutional Review Board (protocol number: 2011P001011). Due
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waiver of informed consent was granted by the Institutional
Review Board. Data on demographics, previous hospitalizations,
medications, and lab tests were collected through the electronic
medical records. Upon study approval, two of the authors
independently collected all the data and were initially blinded
from the objectives of the study. All patient records were
anonymized and de-identified prior to any analysis.
We identified subjects through the hospital infection control
database, which listed all adult VAP patients meeting the
diagnostic criteria of the Center for Disease Control and
Prevention (CDC) for VAP [10]. In brief, the CDC criteria for
the diagnosis of VAP require a combination of clinical symptoms,
imaging results and laboratory tests that lead to the diagnosis of
pneumonia acquired in the hospital and not in the community in
patients intubated and mechanically ventilated for at least
48 hours. Of note, a physician’s diagnosis of pneumonia was not
an acceptable criterion for VAP.
Multidrug resistant bacteria were defined as follows: 1)
Pseudomonas spp. resistant to carbapenems or antipseudomonal
penicillins and an aminoglycoside and/or a fluoroquinolone, 2)
Enterobacteriaceae spp. resistant to carbapenems or third generation
cephalosporins and an aminoglycoside and/or a fluoroquinolone
and 3) Staphylococcus aureus resistant to oxacillin [11]. Patients with
negative tracheal aspirate cultures were excluded from all data
analyses related to multidrug resistance.
Elderly population was defined as people $65 years old [12].
We assessed severity of illness by calculating the simplified acute
physiology (SAPS II) score during the first 24 hours of ICU
admission. We categorized patients as surgical and medical upon
admission to the ICU and we also noted any history of chronic
lung disease according to the electronic medical file. We defined
Candida colonization of the upper respiratory tract as the isolation
of Candida species from respiratory secretions, bronchial washings,
or protected airway specimens. All outcome variables were
calculated defining as day 0 the day of VAP diagnosis.
Statistical analysis
Continuous data were reported as mean (Standard Deviation,
SD) or median (Interquartile Range, IQR). Group comparison
was made using the Mann-Whitney non-parametric test. Count
data were reported as % frequencies and compared using the
Fisher’s exact test. Between-group differences were adjusted by
performing a multivariable logistic regression analysis, for
parameters with p,0.10 at the group analysis. Adjusted effects
were reported as Odds Ratio (OR) with their 95% confidence
interval. Survival analysis was performed using the Kaplan-Meier
method and the log-rank p statistic was reported. All tests were
two-tailed, with significance level set to ,0.05. Stata v11 (College
Station, TX), was used for data analysis.
Results
Epidemiologic characteristics of VAP
Our initial search identified 208 patients with clinically defined
VAP according to the CDC criteria. Of these, 8 patients were
excluded from further analysis because of non-extractable data.
Among the 200 included patients, the mean (SD) age was 55.8 (18)
years, 151 were males while 49 were females and the ratio between
white race and all other races was 4.6:1. Interestingly the ratio
between surgical and non-surgical admissions was 7:1. We also
assessed various comorbidities. Specifically in our population, 21%
had a history of chronic obstructive pulmonary disease (COPD),
21% had diabetes mellitus, 9% had a history of malignancy while
3% had received chemotherapy before the admission that led to
VAP. The mean (SD) SAPS II score upon ICU admission was
39.3 (15.2).
We assessed several outcomes in our population. Median length
of ICU stay was 18 days with an interquartile range (IQR) of 11.5–
25.5 days. Median length of hospital stay was 26 days (IQR:
18-39), while the median length of mechanical ventilation (MV)
was 15 days (IQR: 9-24). 47 out of the 200 evaluable patients with
VAP died during their hospital admission (24%) while 40 died
within 30 days of VAP diagnosis (17%).
The cause of VAP was identifiable in 169/200 patients (84.5%)
and is presented in Table 1. The most common microbial causes
were gram negative pathogens (46.5%), followed by gram positive
bacteria (31.5%), dual gram-positive and gram-negative infections
(5.5%) and fungi (0.5%) Among specific pathogens, the most
common were Staphylococcus spp. (33%), followed by Klebsiella spp.
(11.5%), Enterobacter spp. (10.5%), Pseudomonas spp. (10%) and
Escherichia spp. (6%). Antimicrobial sensitivity data were available
for 147 patients of whom 50 presented with an MDRB (33.3%).
Interestingly, methicillin-resistant Staphylococcus aureus (MRSA) was
isolated from 35 patients (23.8%), while extended spectrum beta
lactamase (ESBL) and carbapenemase producing gram negative
bacteria were isolated from 9 (6.1%) and 7 patients (4.8%),
respectively.
Risk factors for MDRB-caused VAP
Characteristics of the evaluable patients with MDRB-caused
VAP (compared to the patient caused by non-MDR pathogens)
are presented on Table 2. Importantly, the patients did not differ
on SAPS II scores upon ICU admission, or on the type of
admission. However, patients with MDRB-caused VAP were
older (median age 63 vs. 55 years, p=0.02), and a marginally
significant higher percentage were undergoing dialysis before their
most current admission that led to VAP (22% vs.10%, p=0.08).
Also, MDRB were more commonly isolated in patients with late
VAP ($5 days) compared to early VAP (,5 days after hospital
admission) (32% vs.10%, p=0.004).
Outcomes of MDRB-caused VAP
Interestingly, patients with MDR bacteria had significantly
longer ICU stay (median of 19 vs.16 ICU days, p=0.02) and
median MV duration (18 vs.14 days, p=0.03). However, we did not
find any significant increase in 30-day mortality (31% vs.21%, log-
rank p=0.23) in patients with MDRB VAP compared to patients
with VAP caused by non-MDRB. Furthermore, in multiadjusted
analysisfor age, sex, Candidaspp. colonization,and MDRB, only the
effect of age (Hazard Ratio (HR) 1.04; 95% CI 1.01–1.07,
p=0.003, per year increase) was significant (Table 2).
VAP in the geriatric population
Based on our finding that increased age is associated increased
mortality in patients with VAP, and the lack of any studies on the
impact of VAP caused by MDRB in the elderly, we separated our
population in two groups using the cutoff of 65 years which,
although arbitrary, is widely used in studies on the geriatric
population [12]. The results of this stratification are summarized
in Table 3. Indeed, 30-day mortality was significantly higher in the
elderly (log-rank p=0.049). Interestingly, the two populations did
not differ on disease severity on ICU admission (median SAPS II
score 37.5 vs.37, p=0.48). However, the older population had
higher prevalence of pulmonary comorbidities (37% vs. 13%,
p=0.005) and marginally higher prevalence of diabetes (24% vs.
13%, p=0.08).
VAP and Multidrug Resistant Pathogens
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populations, we found that geriatric patients had marginally
higher incidence of MDRB-caused VAP (44% vs. 28%, p=0.07),
but the etiology was significantly different and more than 1/3 of
VAP in this population was caused by MRSA VAP (36% vs. 16%,
p=0.01). Upon multiadjusted analysis, we found that MRSA was
isolated 2.83 times more commonly from VAP patients older than
65 years compared to the younger group (OR 2.83, 95% CI 1.27–
6.32, p=0.01).
Table 1. Etiologic diagnosis of VAP and resistance profiles.
Pathogen Total number (percentage) MDR number (percent resistant)
Staphylococcus aureus 66 (33%) 35 (53%)
Klebsiella spp. 23 (11.5%) 5 (21.7%)
Enterobacter spp. 21 (10.5%) 3 (14.3%)
Pseudomonas spp. 20 (10%) 3 (15%)
Escherichia coli 12 (6%) 0 (0%)
Serratia spp. 9 (4.5%) 0 (0%)
Hemophilus spp. 8 (4%) 0 (0%)
Acinetobacter spp. 7 (3.5%) 0 (0%)
Stenotrophomonas maltophilia 5 (2.5%) 5 (100%)
Other 13 (6.5%) 0 (0%)
Unknown 31 (15.5%) N/A
MDR: multidrug resistant; N/A: not applicable; VAP: ventilator associated pneumonia.
doi:10.1371/journal.pone.0089984.t001
Table 2. Characteristics of MDR vs non-MDR patients with VAP.
MDR (n=50) Non-MDR (n=97) p-value
Demographics
Median age (IQR) 63 (49–75) 55 (39–69) 0.02
Female Sex 20% 29% 0.25
Early VAP (,5 days) 10% 32% 0.004
Non-surgical admission 18% 8% 0.10
Comorbidities
Median SAPS II (IQR) 41 (30–49) 37 (27–49) 0.58
Cancer 8% 11% 0.77
Pulmonary comorbidities 28% 16% 0.13
Dialysis 22% 10% 0.08
Diabetes 26% 15% 0.18
ARDS 12% 10% 0.78
Outcomes
Median ICU stay (IQR) 19(14–30) 16 (10–23) 0.02
Median hospital LOS (IQR) 32 (18–42) 24 (18–34) 0.07
Median MV duration (IQR) 18 (11–30) 14 (8–20) 0.03
Bacteremia 29% 22% 0.41
30-day mortality 31% 21% 0.23
Cox regression analysis for age, sex, MDR, Candida colonization in relation to 30-day mortality
Hazard Ratio 95% Confidence Intervals p-value
Age 1.04 1.01–1.07 0.003
Male gender 0.83 0.36–1.91 0.66
Candida colonization 0.42 0.14–1.23 0.12
MDR 1.12 0.51–2.46 0.77
ARDS: acute respiratory distress syndrome; ICU: intensive care unit; IQR: interquartile range; LOS: length of stay; MDR: multidrug resistant; MV: mechanical ventilation;
VAP: ventilator associated pneumonia.
doi:10.1371/journal.pone.0089984.t002
VAP and Multidrug Resistant Pathogens
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Because, as discussed below, there are reports that link
colonization of the respiratory tract with Candida spp. with higher
mortality in VAP, we evaluated the impact of Candida spp. in our
population. We found that colonized and non-colonized patients
did not differ in VAP etiology or in severity of illness based on the
SAPS II score (36 vs. 37 respectively, p=0.5). Specifically, among
Candida colonized patients, 65% had Gram-negative VAP and
31% Gram-positive while among non-colonized patients 51% had
Gram-negative VAP vs. 41% Gram-positive. When assessing the
effect of Candida spp. colonization of the upper respiratory tract we
did not find any association between Candida spp. and MDR VAP
(23% of MDR had Candida spp. vs. 35% for non-MDR, p=0.18).
Notably, Candida spp. colonization was associated with increased
Table 3. VAP patients stratified by age.
Age $65 (n=72) Age ,65 (n=128) p-value
Demographics
Female gender 28% 23% 0.49
Non-surgical admission 10% 14% 0.51
Comorbidities
Median SAPS II (IQR) 37.5 (32–48) 37 (25–50) 0.48
ARDS 17% 13% 0.70
Cancer 11% 10% 0.81
Dialysis 17% 20% 0.71
Diabetes 24% 13% 0.08
Pulmonary 31% 13% 0.005
Cause of VAP
Gram–/Gram+/Both* 49%/48%/3% 60%/32%/8% 0.08
Klebsiella spp. 11% 15% 0.50
Morganella spp. 0 2% 0.54
Pseudomonas spp. 14% 11% 0.47
Acinetobacter spp. 1% 7% 0.13
Enterobacter spp. 11% 13% 0.81
Stenotrophomonas maltophilia 2% 4% 0.66
Escherichia coli 11% 5% 0.14
Serratia spp. 5% 6% 1.0
Haemophilus spp. 2% 7% 0.26
Staphylococcus aureus 48% 35% 0.11
Enterococcus spp. 3% 2% 0.63
Multidrug-resistant bacteria** 44% 28% 0.07
Carbapenemase producing gram negatives 4% 5% 0.62
Extended spectrum beta lactamase producing gram
negatives
5% 7% 1.0
MRSA 36% 16% 0.01
Outcomes
Bacteremia 19% 25% 0.37
Median LOS (range) 28.5 (5–116) d 25 (8–98) d 0.68
Median ICU stay (range) 19 (4–84) 17 (4–74) 0.17
Median MV duration (range) 14 (1–87) 15 (2–87) 0.85
Day 30 all-cause mortality 30% 15% 0.01
Logistic regression analysis for all variables with p,0.10
Odds Ratio 95% Confidence Intervals p-value
MRSA 2.83 1.27–6.32 0.01
Diabetes 2.10 0.88–5.03 0.10
Pulmonary 2.51 1.07–5.88 0.03
ARDS: Acute respiratory distress syndrome; ICU: intensive care unit; IQR: interquartile range; LOS: length of stay; MRSA: Methicillin-resistant Staphylococcus aureus; MV:
mechanical ventilation; SAPS II: simplified acute physiology score II; VAP: ventilator associated pneumonia.
*Results shown are percentages of the 167 patients for whom a microbiological diagnosis of VAP was successful.
**Results shown are percentages of the 147 patients for whom data on antimicrobial sensitivities were available.
doi:10.1371/journal.pone.0089984.t003
VAP and Multidrug Resistant Pathogens
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(15 vs. 12.5 days, p=0.16) or with higher 30-day mortality (19% vs.
26%, log-rank p=0.14).
Discussion
In this study, we sought to evaluate the effect of MDR organism
isolation in patients with clinically defined VAP so we compared
the outcomes of MDRB VAP patients with non-MDRB VAP and
assessed for confounding factors. Based on the fact that MDR
pathogens are more difficult to combat with traditional antimi-
crobial agents and on reports about the impact of MDR bacteria
on the general population of hospitalized patients [13], we
hypothesized that these pathogens would be associated with worse
outcomes. Of note, the etiology of VAP in our study was similar to
those reported in the literature, as were the rest of the
epidemiologic characteristics, like median age, severity scores
and comorbidities [14–16]. Also, the outcomes of VAP did not
differ from previous reports [14]. Notably, we observed a higher
rate of male patients (3:1 males to females). This is probably a
reflection of the unequal distribution of male and female patients
in our ICUs due to the large number of trauma patients that are
predominantly male and is not different to what was previously
reported in similar settings [17,18].
Indeed, in this study we were able to show that MDRB-caused
VAP isolation does lead to a significant increase in ICU stay and
length of MV in patients with VAP despite the fact that MDRB
and non-MDRB VAP populations did not differ in disease
severity. Interestingly, we did not find a significant increase in
30-day mortality in patients with MDRB-etiology of VAP. This
finding significantly contributes to the hot topic of the relationship
between MDRB VAP and mortality. Specifically, a recent
prospective study assessed the outcomes of ICU-acquired pneu-
monia in association with etiology in 217 VAP patients and 135
patients with non-ventilator associated ICU-acquired pneumonia
and found that resistant organisms were associated with longer
ICU stay and higher rates of microbial persistence after
appropriate treatment but not with increased mortality, a
conclusion that remained even after separating VAP and non-
VAP patients and adjusting for confounders [19]. Similarly,
Depuydt et al. assessed MDRB isolation as a potential cause of
worse outcomes in 192 VAP patients and found that upon
multivariate analysis increased mortality in MDR VAP patients
was explained by higher comorbidities in the same population
[20]. Further, three independent observational studies that focused
on VAP caused by Pseudomonas spp. reached the conclusion that
resistant Pseudomonas spp. were not associated with increased
hospital mortality [21–23]. Finally, a retrospective analysis of 191
Staphylococcus aureus VAP cases concluded that methicillin resistance
was not an independent predictor of 30-day mortality [24].
On the other hand, three studies found that resistant organisms
are associated with increased mortality in VAP patients [25–27]. It
should be noted that, two of these studies did not address the issue
of potential confounders when assessing mortality of MDRB VAP
[27]. Moreover, one of the two reports grouped all cases of VAP
caused by Pseudomonas spp., irrespective of antimicrobial sensitiv-
ities, together with the MDRB VAP group when assessing for
difference in outcomes, a design that further complicates the
interpretation of its findings [25]. Finally, in the third retrospective
study that included 193 VAP cases from a tertiary care center in
Taiwan [27] the rates of microbial causes for VAP were very
different from those usually reported in American hospitals
[14,16], which are similar to those that we found in our study
and thus this conclusion cannot be generalized. Therefore,
although no observational study can provide a definitive answer
to the question, neither our results nor any existing evidence can
support an association between antimicrobial resistance and
mortality in the VAP population.
A very intriguing explanation for these findings would lie in the
complex and recently realized relationship between resistance and
virulence. The acquisition of traits that lead to antimicrobial
resistance often comes with a fitness cost to the bacterial pathogen
[28]. Indeed, Price et al. studied 45 cases of MRSA bacteremia
prospectively and found that patients who were infected with
MRSA isolates with higher vancomycin minimal inhibitory
concentrations had a survival benefit over patients who were
infected with more susceptible MRSA strains [29]. However, we
should note that this is not true in all cases of resistant pathogens.
For example, some multidrug resistant microbial strains, such as
the S. aureus USA300 strain [30] or the P. aeruginosa Liverpool
strain are notorious for being both extensively resistant and highly
virulent and have led to serious and dangerous epidemics [28]. A
more plausible explanation would be that according to the latest
guidelines for the management of hospital-acquired pneumonia
issued by the Infectious Disease Society of America [31], hospital
acquired pneumonia should be treated empirically with broad
spectrum antimicrobial agents if it is diagnosed at 5 or more days
after hospital admission or if several other risk factors apply. VAP
usually falls under this category as it often occurs after 5 days of
admission and in high risk populations. Therefore, VAP is
commonly treated empirically with broad spectrum antimicrobial
agents that can successfully eradicate at least some of the MDR
pathogens. Taking into consideration that the mortality of MDRB
infections often stems from the delayed onset of appropriate
antimicrobial therapy [32], it is possible that any effect on patient
survival due to MDR prokaryotes is obscured in the case of VAP
thanks to the implementation of broad spectrum therapy from
disease onset.
However, such a lenient policy for early broad antimicrobial
coverage doesn’t come free of costs. Anti-infective agents are often
associated with severe side effects especially in populations with
multiple comorbidities such as patients at high risk for MDRB-
VAP. Therefore, every benefit from the implementation of broad
spectrum treatment strategies with multiple antimicrobials in high
risk patients should be weighed against the potential for
therapeutic adverse events in the same population. Nevertheless,
since the lack of significant impact of MDRB VAP on mortality
could be masked by the current therapeutic protocols it would be
wrong to completely underestimate its importance. Indeed, we
found that MDR pathogens are associated with increase in ICU
stay and MV duration both of which are serious causes of
morbidity. Moreover, in agreement with previous reports [33,34],
we showed that late onset VAP is associated with a significantly
higher risk of MDR infection, which corroborates the recommen-
dation of the latest treatment guidelines. Consequently, on the face
of these findings, we believe that randomized trials that compare
current treatment strategies with a more cautious approach that
starts with narrow spectrum antimicrobials are imperative
especially in the high risk groups and should be performed before
any changes in the current recommendations are implemented.
Based on the significant impact of age on mortality in VAP, we
also assessed the etiologic diagnosis of VAP in patients $65 years
old. Notably, we found that the probability of MRSA VAP is
almost tripled in the population, an effect that is independent of
other comorbidities as proven by multivariable logistic regression
analysis. Surprisingly, the significance of VAP in this population
has not been studied in detail. We were able to find only two
recent studies that evaluated the association between MRSA VAP
VAP and Multidrug Resistant Pathogens
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higher risk for MRSA [24,35]. Our study goes even further by
showing that 36% of the elderly patients with microbiologically
defined VAP are infected with MRSA, thus revealing the
magnitude of the problem. This result is most likely associated
with the living conditions of the elderly population or with their
more frequent hospitalization which is associated with an
increased risk of MRSA colonization [36] rather than with age
itself. However, given the strikingly high prevalence of MRSA in
the elderly VAP patients, this association should be seriously taken
into consideration when treating geriatric people with VAP.
Because previous reports indicated that Candida spp. coloniza-
tion of the upper respiratory tract is associated with increased risk
of MDRB isolation and worse outcomes in VAP patients [11,37],
we evaluated this potential confounding factor in detail. We found
that, in our population, colonization of the upper respiratory tract
by Candida spp. is an important predictor of morbidity as it
significantly prolongs ICU stay. Notably, we did not find any
relationship between Candida and increased mortality in VAP. To
our knowledge, this is the first study that evaluated the impact of
Candida spp. colonization in a consecutive population of patients
with clinically defined VAP. Two recent studies that found an
association between Candida spp. colonization and mortality were
focusing in a subset of the VAP population that did not have an
identified bacterial pathogen isolated from their tracheal cultures
[9,38]. Another study that found increased mortality in colonized
patients with suspected VAP excluded all patients that were
colonized or infected with MRSA or Pseudomonas spp. thus limiting
the generalization of the results in the total VAP population [37].
Moreover, in agreement with our findings, an earlier report that
studied the effect of Candida spp. colonization on outcomes in
immunocompetent individuals with mechanical ventilation found
that Candida spp. were associated with a higher ICU stay but not
with higher mortality [7]. Finally, based on a previous study that
found an association between Candida spp. colonization and MDR
in patients with suspected VAP [11], we also assessed whether the
prolonged ICU stay that we found was confounded by a higher
rate of MDR in our population but we did not find such a
relationship. Therefore, based on our findings, Candida spp. should
be evaluated as an independent factor that might be associated
with higher morbidity but not mortality in patients with clinically
defined VAP.
Limitations of our study include its retrospective design which
precludes any discussion on causative relationships between
exposures and outcomes. Indisputable cause and effect relation-
ships can only be proven with interventional studies, which are
often non-feasible in the case of MDR infections [39]. Therefore,
data from observational studies indicating associations could be
particularly useful in clinical decision making in such cases. Also,
due to missing data from the electronic medical records, we had a
relatively high number of cases with unknown antimicrobial
sensitivities. Finally, we should note that to eliminate subjectivity in
reporting cases of VAP, the CDC has very recently issued new
criteria for defining and reporting ventilator-associated events
[40]. Although it will take some time until all reporting and
surveillance systems of hospitals have shifted toward the new
definitions, it would be particularly interesting to investigate how
this new effort would impact our findings and this should be the
target of future studies in the field.
In conclusion, our study provides evidence that MDRB isolation
is associated with increased morbidity but not mortality in patients
with VAP. Also, late onset ($5 days from admission) VAP is
associated with a significantly higher rate of multidrug resistance.
Interestingly, age is an independent predictor of mortality in VAP
and geriatric patients have an almost threefold increased risk for
MRSA VAP. These findings should be further confirmed in future
multicenter trials.
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